Patents Assigned to PHAROSGEN
  • NOVEL USE OF ANTICANCER AGENT PRODRUG CONJUGATE
    Publication number: 20250302981
    Abstract: The present invention provides a pharmaceutical composition for the treatment of cancer having KRAS variant genotype or PTEN protein loss genotype, comprising an anti-cancer chemotherapeutic prodrug conjugate consisting of an albumin binding moiety, a linker, and an anti-cancer chemotherapeutic agent, for the effective treatment of cancers having KRAS variant genotype or PTEN protein loss genotype, which are known to be refractory cancers.
    Type: Application
    Filed: February 15, 2021
    Publication date: October 2, 2025
    Applicants: UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION, PHAROSGEN, THE ASAN FOUNDATION, SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Sanghwan KIM, Sang Yoon KIM, Youngro BYUN, Hanhee CHO
  • Methods of inhibiting pathological angiogenesis with doppel-targeting molecules
    Patent number: 10501549
    Abstract: Described herein are doppel-targeting molecules useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (PAH), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: December 10, 2019
    Assignees: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, UNIVERSITY OF ULSAN, KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, PHAROSGEN
    Inventors: Youngro Byun, In San Kim, Ahmed Al-Hilal Taslim, Sang-Yoon Kim, Ye Ji Jang
  • Methods of inhibiting pathological angiogenesis with doppel-targeting molecules
    Patent number: 10202459
    Abstract: Described herein are doppel-targeting molecules useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (PAH), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: February 12, 2019
    Assignees: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, UNIVERSITY OF ULSAN, KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, PHAROSGEN
    Inventors: Youngro Byun, In San Kim, Ahmed Al-Hilal Taslim, Sang-Yoon Kim, Ye Ji Jang
  • METHODS OF INHIBITING PATHOLOGICAL ANGIOGENESIS WITH DOPPEL-TARGETING MOLECULES
    Publication number: 20170260278
    Abstract: Described herein are doppel-targeting molecules useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (PAH), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described.
    Type: Application
    Filed: March 6, 2017
    Publication date: September 14, 2017
    Applicants: SEOUL NATIONAL UNIVERSITY, UNIVERSITY OF ULSAN, KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, PHAROSGEN
    Inventors: Youngro Byun, In San Kim, Ahmed Al-Hilal Taslim, Sang-Yoon Kim, Ye Ji Jang